---
document_datetime: 2025-12-02 04:56:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/opzelura.html
document_name: opzelura.html
version: success
processing_time: 0.1077511
conversion_datetime: 2025-12-24 08:50:09.503865
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Opzelura

[RSS](/en/individual-human-medicine.xml/67670)

##### Authorised

This medicine is authorised for use in the European Union

ruxolitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Opzelura](#news-on)
- [More information on Opzelura](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Opzelura is a medicine used for treating non-segmental vitiligo, a disease that causes patches of skin to lose colour on both sides of the body. In patients with vitiligo, the immune system (the body's natural defences) attacks melanocytes (the skin cells that make pigment), causing patches of pale pink or white skin (depigmentation). Opzelura is used in adults and adolescents from 12 years of age with non-segmental vitiligo that also affects the face.

Opzelura contains the active substance ruxolitinib.

Expand section

Collapse section

## How is Opzelura used?

Opzelura can only be obtained with a prescription and treatment should be started and supervised by a doctor with experience in the diagnosis and treatment of non-segmental vitiligo.

Opzelura is available as a cream to be applied on the depigmented skin twice a day. Opzelura should not be applied to more than 10% of the body at the same time.

Treatment may be needed for more than 6 months to obtain satisfactory repigmentation of the skin (return of skin colour). The doctor may stop treatment if there is no satisfactory improvement after one year of treatment.

For more information about using Opzelura, see the package leaflet or contact your doctor or pharmacist.

## How does Opzelura work?

The active substance in Opzelura, ruxolitinib, works by blocking enzymes known as Janus kinase (JAK) 1 and 2, which are involved in the activity of a substance called interferon-gamma (IFN-gamma). In vitiligo, IFN-gamma is thought to play a role in the activity of the cells of the immune system that attack melanocytes. By blocking JAK1 and JAK2, ruxolitinib reduces the immune system's ability to destroy melanocytes, allowing them to produce pigment.

## What benefits of Opzelura have been shown in studies?

In 2 main studies, Opzelura was shown to improve repigmentation compared with placebo (dummy treatment).

The main measure of effectiveness was the proportion of patients who achieved an improvement of at least 75% in the pigmentation of their face as measured using a standard score for facial vitiligo (F-VASI75) after 6 months.

The 2 studies involved a total of 661 patients with non-segmental vitiligo. On average, around 31% of patients who received Opzelura achieved an improvement of at least 75% in the pigmentation of their face after 6 months of treatment, compared with around 10% of those who received placebo. Using a standard score for total body pigmentation (T-VASI50), the studies further showed that, after 6 months, total body pigmentation improved by at least 50% in 22% of patients who used Opzelura compared with 6% of those receiving placebo.

## What are the risks associated with Opzelura?

For the full list of side effects and restrictions with Opzelura, see the package leaflet.

The most common side effect with Opzelura (which may affect up to 1 in 10 people) is acne at the site where the medicine was applied.

Women who are pregnant or breastfeeding must not use Opzelura.

## Why is Opzelura authorised in the EU?

Opzelura has been shown to have beneficial effects on the repigmentation of the skin in patients with non-segmental vitiligo. In terms of safety, the side effects of Opzelura are considered acceptable. While ruxolitinib medicines taken by mouth are associated with serious side effects, these effects are not expected to occur with Opzelura since it is used as a cream, provided that it is not used on more than 10% of the body in one application.

The European Medicines Agency therefore decided that Opzelura's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Opzelura?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Opzelura have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Opzelura are continuously monitored. Suspected side effects reported with Opzelura are carefully evaluated and any necessary action taken to protect patients.

## Other information about Opzelura

Opzelura received a marketing authorisation valid throughout the EU on 19 April 2023.

Opzelura : EPAR - Medicine overview

Reference Number: EMA/100444/2023

English (EN) (119.97 KB - PDF)

**First published:** 20/04/2023

[View](/en/documents/overview/opzelura-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-720)

български (BG) (143.77 KB - PDF)

**First published:**

20/04/2023

[View](/bg/documents/overview/opzelura-epar-medicine-overview_bg.pdf)

español (ES) (119.61 KB - PDF)

**First published:**

20/04/2023

[View](/es/documents/overview/opzelura-epar-medicine-overview_es.pdf)

čeština (CS) (140.92 KB - PDF)

**First published:**

20/04/2023

[View](/cs/documents/overview/opzelura-epar-medicine-overview_cs.pdf)

dansk (DA) (118.79 KB - PDF)

**First published:**

20/04/2023

[View](/da/documents/overview/opzelura-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.61 KB - PDF)

**First published:**

20/04/2023

[View](/de/documents/overview/opzelura-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.21 KB - PDF)

**First published:**

20/04/2023

[View](/et/documents/overview/opzelura-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.91 KB - PDF)

**First published:**

20/04/2023

[View](/el/documents/overview/opzelura-epar-medicine-overview_el.pdf)

français (FR) (127.22 KB - PDF)

**First published:**

20/04/2023

[View](/fr/documents/overview/opzelura-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.23 KB - PDF)

**First published:**

20/04/2023

[View](/hr/documents/overview/opzelura-epar-medicine-overview_hr.pdf)

italiano (IT) (118.73 KB - PDF)

**First published:**

20/04/2023

[View](/it/documents/overview/opzelura-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.03 KB - PDF)

**First published:**

20/04/2023

[View](/lv/documents/overview/opzelura-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (157.66 KB - PDF)

**First published:**

20/04/2023

[View](/lt/documents/overview/opzelura-epar-medicine-overview_lt.pdf)

magyar (HU) (141.55 KB - PDF)

**First published:**

20/04/2023

[View](/hu/documents/overview/opzelura-epar-medicine-overview_hu.pdf)

Malti (MT) (143.31 KB - PDF)

**First published:**

20/04/2023

[View](/mt/documents/overview/opzelura-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.77 KB - PDF)

**First published:**

20/04/2023

[View](/nl/documents/overview/opzelura-epar-medicine-overview_nl.pdf)

polski (PL) (143.4 KB - PDF)

**First published:**

20/04/2023

[View](/pl/documents/overview/opzelura-epar-medicine-overview_pl.pdf)

português (PT) (119.94 KB - PDF)

**First published:**

20/04/2023

[View](/pt/documents/overview/opzelura-epar-medicine-overview_pt.pdf)

română (RO) (140.2 KB - PDF)

**First published:**

20/04/2023

[View](/ro/documents/overview/opzelura-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.91 KB - PDF)

**First published:**

20/04/2023

[View](/sk/documents/overview/opzelura-epar-medicine-overview_sk.pdf)

slovenščina (SL) (139.17 KB - PDF)

**First published:**

20/04/2023

[View](/sl/documents/overview/opzelura-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.94 KB - PDF)

**First published:**

20/04/2023

[View](/fi/documents/overview/opzelura-epar-medicine-overview_fi.pdf)

svenska (SV) (118.53 KB - PDF)

**First published:**

20/04/2023

[View](/sv/documents/overview/opzelura-epar-medicine-overview_sv.pdf)

Opzelura : EPAR - Risk management plan

English (EN) (425.76 KB - PDF)

**First published:** 20/04/2023

**Last updated:** 28/07/2025

[View](/en/documents/rmp/opzelura-epar-risk-management-plan_en.pdf)

## Product information

Opzelura : EPAR -  Product Information

English (EN) (485.89 KB - PDF)

**First published:** 20/04/2023

**Last updated:** 20/08/2025

[View](/en/documents/product-information/opzelura-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-898)

български (BG) (408.8 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/bg/documents/product-information/opzelura-epar-product-information_bg.pdf)

español (ES) (368 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/es/documents/product-information/opzelura-epar-product-information_es.pdf)

čeština (CS) (417.38 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/cs/documents/product-information/opzelura-epar-product-information_cs.pdf)

dansk (DA) (351.51 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/da/documents/product-information/opzelura-epar-product-information_da.pdf)

Deutsch (DE) (369.58 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/de/documents/product-information/opzelura-epar-product-information_de.pdf)

eesti keel (ET) (347.51 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/et/documents/product-information/opzelura-epar-product-information_et.pdf)

ελληνικά (EL) (430.12 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/el/documents/product-information/opzelura-epar-product-information_el.pdf)

français (FR) (441.72 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/fr/documents/product-information/opzelura-epar-product-information_fr.pdf)

hrvatski (HR) (393.73 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/hr/documents/product-information/opzelura-epar-product-information_hr.pdf)

íslenska (IS) (445.32 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/is/documents/product-information/opzelura-epar-product-information_is.pdf)

italiano (IT) (376.34 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/it/documents/product-information/opzelura-epar-product-information_it.pdf)

latviešu valoda (LV) (398.2 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/lv/documents/product-information/opzelura-epar-product-information_lv.pdf)

lietuvių kalba (LT) (429.76 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/lt/documents/product-information/opzelura-epar-product-information_lt.pdf)

magyar (HU) (431.71 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/hu/documents/product-information/opzelura-epar-product-information_hu.pdf)

Malti (MT) (512.92 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/mt/documents/product-information/opzelura-epar-product-information_mt.pdf)

Nederlands (NL) (458.17 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/nl/documents/product-information/opzelura-epar-product-information_nl.pdf)

norsk (NO) (357.52 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/no/documents/product-information/opzelura-epar-product-information_no.pdf)

polski (PL) (527.94 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/pl/documents/product-information/opzelura-epar-product-information_pl.pdf)

português (PT) (348.96 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/pt/documents/product-information/opzelura-epar-product-information_pt.pdf)

română (RO) (401.24 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/ro/documents/product-information/opzelura-epar-product-information_ro.pdf)

slovenčina (SK) (452.29 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/sk/documents/product-information/opzelura-epar-product-information_sk.pdf)

slovenščina (SL) (403.63 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/sl/documents/product-information/opzelura-epar-product-information_sl.pdf)

Suomi (FI) (441.22 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/fi/documents/product-information/opzelura-epar-product-information_fi.pdf)

svenska (SV) (327.23 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

20/08/2025

[View](/sv/documents/product-information/opzelura-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000256180 03/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Opzelura : EPAR -  All Authorised Presentations

English (EN) (37.08 KB - PDF)

**First published:** 20/04/2023

**Last updated:** 22/06/2023

[View](/en/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-424)

български (BG) (34.5 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/bg/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_bg.pdf)

español (ES) (36.43 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/es/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.48 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/cs/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.03 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/da/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (10.03 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/de/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (9.74 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/et/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.82 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/el/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_el.pdf)

français (FR) (10.14 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/fr/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.82 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/hr/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/is/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_is.pdf)

italiano (IT) (9.52 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/it/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.61 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/lv/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.33 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/lt/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.59 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/hu/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.98 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/mt/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (35.01 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/nl/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (35.22 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/no/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_no.pdf)

polski (PL) (56.79 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/pl/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_pl.pdf)

português (PT) (35.14 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/pt/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.74 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/ro/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.71 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/sk/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (43.11 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/sl/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.02 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/fi/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.15 KB - PDF)

**First published:**

20/04/2023

**Last updated:**

22/06/2023

[View](/sv/documents/all-authorised-presentations/opzelura-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Opzelura Active substance ruxolitinib phosphate International non-proprietary name (INN) or common name ruxolitinib Therapeutic area (MeSH) Vitiligo Anatomical therapeutic chemical (ATC) code D11AH

### Pharmacotherapeutic group

Other dermatological preparations

### Therapeutic indication

Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

## Authorisation details

EMA product number EMEA/H/C/005843 Marketing authorisation holder

Incyte Biosciences Distribution B.V.

Paasheuvelweg 25

Opinion adopted 23/02/2023 Marketing authorisation issued 19/04/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Opzelura : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (156.76 KB - PDF)

**First published:** 28/07/2025

**Last updated:** 20/08/2025

[View](/en/documents/procedural-steps-after/opzelura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Opzelura : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (162.05 KB - PDF)

**First published:** 22/06/2023

**Last updated:** 28/07/2025

[View](/en/documents/procedural-steps-after/opzelura-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Opzelura : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/135534/2023

English (EN) (5.1 MB - PDF)

**First published:** 20/04/2023

[View](/en/documents/assessment-report/opzelura-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Opzelura

Adopted

Reference Number: EMA/CHMP/27927/2023

English (EN) (117.47 KB - PDF)

**First published:** 24/02/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-opzelura_en.pdf)

#### News on Opzelura

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023) 24/02/2023

#### More information on Opzelura

- [EMEA-002618-PIP02-20-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002618-pip02-20-m01)
- [EMEA-002618-PIP04-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002618-pip04-23)
- [Opzelura - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/opzelura)
- [An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of OpzeluraTM (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000413)

**This page was last updated on** 20/08/2025

## Share this page

[Back to top](#main-content)